MARI — Marinomed Biotech AG Share Price
0.000.00%
Last trade - 00:00- €25.25m
- €53.43m
- €9.18m
- 16
- 12
- 76
- 23
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 2.8 | ||
| PEG Ratio (f) | 0.04 | ||
| EPS Growth (f) | 388.46% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.93 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -84.87% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 6.14 | 8.12 | 11.63 | 11.28 | 9.18 | 19.7 | 30.8 | 14.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +388.46 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Marinomed Biotech AG, formerly known as Marinomed Biotechnologie GmbH, is an Austria-based biopharmaceutical company. The Company operates in two segments such as Virology and Immunology. It develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose, platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients, this technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. The company also develops treatments for type I allergies and autoimmune diseases.
Directors
- Simon Nebel CSU (55)
- Andreas Grassauer CMG (50)
- Ute Lassnig VSU (49)
- Pascal Schmidt CFO
- Helmut Baranyovszki FID
- Eva Prieschl-Grassauer CSO (51)
- Renate Moser VBD
- Brigitte Ederer SUB (65)
- Gernot Hofer SUB (39)
- Karl Lankmayr SUB (41)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- December 31st, 2006
- Public Since
- February 1st, 2019
- No. of Employees
- 47
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Vienna Stock Exchange
- Shares in Issue
- 1,778,333
- Address
- Hovengasse 25, KORNEUBURG, 2100
- Web
- https://www.marinomed.com/
- Phone
- +43 226290300
- Contact
- Stephanie Kniep
- Auditors
- Bdo Austria GmbH Wirtschaftsprufungs Und Steuerberatungsgese
Upcoming Events for MARI
Marinomed Biotech AG Annual Shareholders Meeting
Q2 2025 Marinomed Biotech AG Earnings Release
FAQ
What is the Marinomed Biotech AG share price?
As of Today at 20:54 UTC, shares in Marinomed Biotech AG are trading at €14.20. This share price information is delayed by 15 minutes.
How has the Marinomed Biotech AG share price performed this year?
Shares in Marinomed Biotech AG last closed at €14.20 and the price had moved by -29% over the past 365 days. In terms of relative price strength the Marinomed Biotech AG share price has underperformed the FTSE Global All Cap Index by -34.44% over the past year.
What are the analyst and broker recommendations for Marinomed Biotech AG?
The overall consensus recommendation for Marinomed Biotech AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Marinomed Biotech AG dividend yield?
Marinomed Biotech AG does not currently pay a dividend.
Does Marinomed Biotech AG pay a dividend?
Marinomed Biotech AG does not currently pay a dividend.
When does Marinomed Biotech AG next pay dividends?
Marinomed Biotech AG does not currently pay a dividend.
How do I buy Marinomed Biotech AG shares?
To buy shares in Marinomed Biotech AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Marinomed Biotech AG?
As of the previous close price of €14.20, shares in Marinomed Biotech AG had a market capitalisation of €25.25m.
Where are Marinomed Biotech AG shares listed?
Here are the trading details for Marinomed Biotech AG:
- Country of listing: Austria
- Exchange: VIE
- Ticker Symbol: MARI
What kind of share is Marinomed Biotech AG?
Based on an overall assessment of its quality, value and momentum Marinomed Biotech AG is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Marinomed Biotech AG share price forecast for 2025?
The analyst consensus target price for shares in Marinomed Biotech AG is €75.00. That is 428.17% above the last closing price of €14.20.
Analysts covering Marinomed Biotech AG currently have a consensus Earnings Per Share (EPS) forecast of €1.04 for the next financial year.
Find out moreWhat is the trend in the Marinomed Biotech AG share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Marinomed Biotech AG. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +49.32%.
As of the last closing price of €14.20, shares in Marinomed Biotech AG were trading +24.95% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Marinomed Biotech AG PE Ratio?
The Marinomed Biotech AG PE ratio based on its reported earnings over the past 12 months is 2.8. The shares last closed at €14.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Marinomed Biotech AG?
Marinomed Biotech AG's management team is headed by:
- Simon Nebel - CSU
- Andreas Grassauer - CMG
- Ute Lassnig - VSU
- Pascal Schmidt - CFO
- Helmut Baranyovszki - FID
- Eva Prieschl-Grassauer - CSO
- Renate Moser - VBD
- Brigitte Ederer - SUB
- Gernot Hofer - SUB
- Karl Lankmayr - SUB